Cx 401

Drug Profile

Cx 401

Alternative Names: Cx401; Ontaril

Latest Information Update: 04 Dec 2012

Price : $50

At a glance

  • Originator Cellerix
  • Developer Axcan Pharma; Cellerix
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rectal fistula

Highest Development Phases

  • Discontinued Rectal fistula

Most Recent Events

  • 21 Jun 2011 Discontinued - Phase-III for Rectal fistula in Austria (Intralesional)
  • 21 Jun 2011 Discontinued - Phase-III for Rectal fistula in Belgium (Intralesional)
  • 21 Jun 2011 Discontinued - Phase-III for Rectal fistula in Czech Republic (Intralesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top